公开(公告)号：US20250043027A1

公开(公告)日：2025-02-06

申请号：US18926965

申请日：2024-10-25

Applicant: Kashiv BioSciences, LLC

Inventor： Bruce Weaver ,  Om Narayan ,  Sumit Maheshkumar Shah

IPC: C07K16/42 ,  A61K9/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26

Abstract: The present disclosure describes pharmaceutically stable high concentration liquid formulations of antibody. Such formulations comprise, in addition to the antibody, at least one anti-aggregating agent selected from arginine or lysine, buffer and poloxamer 188. In addition, the present disclosure provides high concentrated antibody formulation having high monomer, low aggregates and desirable viscosity.

公开(公告)号：US12208066B2

公开(公告)日：2025-01-28

申请号：US18190416

申请日：2023-03-27

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas Chen

IPC: A61K31/045 ,  A61K9/00 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/4745 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C07K16/42 ,  C12N5/0783 ,  C12N5/16 ,  C12P5/00

Abstract: The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier.

公开(公告)号：US12187772B2

公开(公告)日：2025-01-07

申请号：US18308892

申请日：2023-04-28

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Jie Dai ,  Maria del Pilar Molina-Portela ,  Ella Ioffe ,  Markus Mohrs

IPC: A61K38/20 ,  A61K47/68 ,  A61P35/00 ,  C07K1/22 ,  C07K14/54 ,  C07K16/42 ,  A61K38/00

Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy and uses thereof. Certain IL10 agonists disclosed herein comprise an IgG Fc domain, a linker moiety, and an IL10 moiety.

公开(公告)号：US20240392034A1

公开(公告)日：2024-11-28

申请号：US18802877

申请日：2024-08-13

Applicant: MORPHOSYS AG

Inventor： Stefan Härtle

IPC: C07K16/30 ,  A61P35/00 ,  C07K14/76 ,  C07K16/42 ,  G01N33/49 ,  G01N33/561 ,  G01N33/574

Abstract: Applicant discloses an anti-idiotypic antibody to MOR202. which when fused to human albumin. shifted the antibody in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.

公开(公告)号：US20240342404A1

公开(公告)日：2024-10-17

申请号：US18751627

申请日：2024-06-24

Applicant: Norton (Waterford) Limited

Inventor： Mark Milton-Edwards ,  Guilherme Safioti ,  Lena Granovsky ,  Michael Reich

IPC: A61M15/00 ,  A61B5/00 ,  A61B5/08 ,  A61K31/138 ,  A61M11/00 ,  C07K16/24 ,  C07K16/28 ,  C07K16/42 ,  G16H20/10 ,  G16H20/13 ,  G16H50/30 ,  G16H50/70

CPC classification number: A61M15/009 ,  A61B5/0826 ,  A61B5/4848 ,  A61B5/7275 ,  A61K31/138 ,  A61M15/0001 ,  A61M15/0025 ,  A61M15/003 ,  A61M15/008 ,  A61M15/0091 ,  C07K16/244 ,  C07K16/247 ,  C07K16/2866 ,  C07K16/4291 ,  G16H20/10 ,  G16H20/13 ,  G16H50/30 ,  G16H50/70 ,  A61M11/00 ,  A61M15/0026 ,  A61M2202/064 ,  A61M2205/05 ,  A61M2205/18 ,  A61M2205/3327 ,  A61M2205/3331 ,  A61M2205/3358 ,  A61M2205/3584 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2230/30 ,  A61M2230/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52

Abstract: Provided is a system (10) for determining a probability of an asthma exacerbation in a subject. The system comprises an inhaler (100) for delivering a rescue medicament to the subject. The inhaler has a use-detection system (12B) configured to determine a rescue inhalation performed by the subject using the first inhaler. A sensor system (12A) is configured to measure a parameter relating to airflow during the rescue inhalation. The system further comprises a processor (14) configured to determine a number of the rescue inhalations during a first time period, and receive the parameter measured for at least some of the rescue inhalations. The processor determines, using a weighted model, the probability of the asthma exacerbation based on the number of rescue inhalations and the parameters. The model is weighted such that the number of rescue inhalations is more significant in the probability determination than the parameters.

公开(公告)号：US20240327526A1

公开(公告)日：2024-10-03

申请号：US18381745

申请日：2023-10-19

Applicant: AMGEN INC.

Inventor： Huiquan HAN ,  Xiaolan ZHOU ,  Qing CHEN ,  Mei-Mei TSAI

IPC: C07K16/28 ,  A61K39/00 ,  A61P21/00 ,  C07K16/42 ,  C07K16/46

CPC classification number: C07K16/2863 ,  A61P21/00 ,  C07K16/42 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.

公开(公告)号：US20240327508A1

公开(公告)日：2024-10-03

申请号：US18744537

申请日：2024-06-14

Applicant: Xencor, Inc.

Inventor： Aaron Keith Chamberlain ,  Bassil Dahiyat ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar

IPC: C07K16/18 ,  A61K39/00 ,  C07K14/715 ,  C07K16/08 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  C07K16/42

CPC classification number: C07K16/18 ,  C07K14/7151 ,  C07K16/082 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2893 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4291 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/90 ,  C07K2319/30 ,  Y02A50/30

Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.

公开(公告)号：US20240327482A1

公开(公告)日：2024-10-03

申请号：US18600288

申请日：2024-03-08

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel Getts ,  Yuxiao Wang ,  Bruce McCreedy, Jr.

IPC: C07K14/525 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/42

CPC classification number: C07K14/525 ,  C07K16/283 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/303 ,  C07K16/32 ,  C07K16/4291 ,  C07K2317/31 ,  C07K2319/30

Abstract: Compositions and methods for making and using therapeutic agents comprising myeloid cell specific engagers, used for immunotherapy of cancer or infection.

公开(公告)号：US20240317861A1

公开(公告)日：2024-09-26

申请号：US18539509

申请日：2023-12-14

Applicant: GENMAB A/S

Inventor： Isil ALTINTAS ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rik RADEMAKER ,  Paul PARREN ,  Bart DE GOEIJ

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/42

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/4258 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US12048705B2

公开(公告)日：2024-07-30

申请号：US17281016

申请日：2019-10-03

Applicant: AVM Biotechnology, LLC

Inventor： Theresa Deisher

IPC: A61K31/573 ,  A61K9/00 ,  A61K47/54 ,  A61P3/10 ,  A61P25/14 ,  A61P31/18 ,  A61P35/00 ,  A61P37/06 ,  C07K16/42

CPC classification number: A61K31/573 ,  A61K9/0019 ,  A61K9/0053 ,  A61K47/547 ,  A61P3/10 ,  A61P25/14 ,  A61P31/18 ,  A61P35/00 ,  A61P37/06 ,  C07K16/4283

Abstract: This invention pertains to pharmaceutical compositions comprising a glucocorticoid for use in the treatment of diseases by immunoablation. The compositions of the invention may be for use in the treatment of diseases that are mediated by immune cells such as lymphocytes.